Payer sentiments, outcomes, comorbidities, and more for innovative therapies treating scleroderma
This white paper discusses the strategy to create an integrated and innovative program capable of demonstrating the “value” of a therapy for scleroderma, as well as clinical utility and therapeutic novelty.
